Ajit Brar

Dr. Ajit Brar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2026 in Exploration of Cardiology
Verified
Journal Article
Open access
PDF file
RPRazieh Parizad
Razieh Parizad
JHJuniali Hatwal
Juniali Hatwal
Ajit BrarAjit Brar
Ajit Brar
Akash BattaAkash Batta
Akash Batta
MSMohammadreza Taban Sadeghi
Mohammadreza Taban Sadeghi
BMBishav Mohan
Bishav Mohan
Background: Patients with pre-existing heart failure (HF) are particularly vulnerable to adverse outcomes following coronavirus disease 2019 (COVID-19). Understanding of the long-term cardiovascular sequelae of COVID-19 in this high-risk group is essential to improve post-infection management and outcomes. Methods: A systematic review of PubMed, Scopus, Web of Science, and Embase was conducted to identify peer-reviewed studies published between 2020 and 2025. Eligible studies included adults with a confirmed diagnosis of HF prior to COVID-19 infection and reported cardiovascular outcomes assessed at least 12 weeks after the acute phase. Data were extracted on patient demographics, HF subtype, cardiovascular outcomes, quality of life (QoL), and management approaches. Results: Forty-five studies met the inclusion criteria, encompassing heterogeneous but predominantly high-income country populations across multiple regions and HF phenotypes. COVID-19 was associated with increased HF symptoms, hospital readmissions 28% [95% confidence interval (CI) 24–32%] at 12 months, and mortality 18% (95% CI 15–22%) at ≥ 12 months. Patients with HF with reduced ejection fraction (HFrEF) had a 1.4-fold greater readmission risk than HF with preserved ejection fraction (HFpEF). Mechanistic data implicated persistent myocardial inflammation, endothelial dysfunction, and autonomic dysregulation. Functional capacity declined, with a mean 68-meter reduction in six-minute walk distance (6MWD). Vaccination was associated with a ~40% reduction in mortality and major adverse cardiovascular events (MACE). Discussion: COVID-19 is associated with a sustained cardiovascular burden in individuals with HF, underscoring the importance of long-term surveillance, optimization of guideline-directed medical therapy, and structured rehabilitation. Standardized, prospective studies are needed to elucidate causal mechanisms and refine post-COVID management strategies.

1 March 2026 in Vascular Health and Risk Management
Verified
Journal Article
Open access
RPRazieh Parizad
Razieh Parizad
JHJuniali Hatwal
Juniali Hatwal
MSMohammadreza Taban Sadeghi
Mohammadreza Taban Sadeghi
Ajit BrarAjit Brar
Ajit Brar
RDRupak Desai
Rupak Desai
BMBishav Mohan
Bishav Mohan
Heart failure with preserved ejection fraction (HFpEF) has emerged as the predominant of heart failure (HF), particularly among aging populations and individuals with a high burden of comorbidities. Its underlying pathophysiological mechanisms are complex, multifactorial and, heterogeneous. This systematic review aims to synthesize contemporary evidence on the epidemiology, pathophysiology, diagnostic challenges, and therapeutic strategies for HFpEF, with especially emphasis on emerging clinical approaches and future research directions. A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025. Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF. HFpEF now accounts for more than 50% of all HF diagnoses worldwide. Although it shares overlapping clinical features with other cardiovascular (CV) and systemic disorders, recent advances in echocardiographic techniques and the use of circulating biomarkers have substantially improved diagnostic accuracy. Current management strategies primarily focus on comorbidity control, optimization of volume status, structured exercise and rehabilitation programs, and the adoption of novel pharmacological therapies, most notably sodium glucose cotransporter 2 (SGLT2) inhibitors. Notable recent advances include the nonsteroidal mineralocorticoid receptor antagonist finerenone, which demonstrated reductions in worsening HF events and CV mortality in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and HFpEF in the FINEARTS-HF trial. In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes. HFpEF continues to pose substantial diagnostic and therapeutic challenges owing to its marked heterogeneity and historically limited treatment options. Advances in phenotypic classification, personalized therapeutic strategies, and integrated multidisciplinary care models are critical for improving long-term outcomes in this expanding patient population. The emergence of finerenone and glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists, including semaglutide and tirzepatide, represents a promising extension beyond SGLT2 inhibitors, particularly in cardiometabolic and obesity-driven HFpEF. However, further incorporation into clinical guidelines and validation through real-world evidence remain necessary.

1 March 2026 in Vascular Health and Risk Management
Verified
Journal Article
Open access
RPRazieh Parizad
Razieh Parizad
JHJuniali Hatwal
Juniali Hatwal
Ajit BrarAjit Brar
Ajit Brar
RDRupak Desai
Rupak Desai
Akash BattaAkash Batta
Akash Batta
BMBishav Mohan
Bishav Mohan
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide. Conventional risk prediction models often demonstrate suboptimal calibration and limited generalizability across populations. Artificial intelligence (AI) approaches, including machine learning (ML) and deep learning (DL), enable integration of multimodal clinical and imaging data for individualized cardiovascular risk estimation. To evaluate the applications, predictive performance, and translational limitations of AI models for cardiovascular risk prediction within an umbrella review framework. PubMed, Scopus, and Web of Science were systematically searched for studies published between January 2015 and October 2025 investigating AI-based prediction of cardiovascular outcomes. Eligible designs included randomized controlled trials (RCTs), cohort studies, systematic reviews, and meta-analyses. Predictive performance was the primary outcome, mainly assessed using the area under the receiver operating characteristic curve (AUC). Methodological quality was evaluated using established risk-of-bias tools. From 3500 identified records, 48 studies (8 RCTs, 28 cohort studies, and 12 systematic reviews or meta-analyses) were included in the final analysis. AI models achieved AUC values greater than 0.90 in more than 70% of imaging-based studies. Evidence synthesis showed predominant reliance on internal validation, inconsistent calibration reporting, and limited evaluation of algorithmic fairness. Multimodal data integration improved detection of coronary artery disease (CAD) and heart failure (HF). Wearable monitoring was associated with 18–25% lower hospitalization rates compared with usual care. AI improves predictive accuracy in cardiovascular risk assessment. Despite strong discrimination performance (AUC), methodological heterogeneity, insufficient calibration assessment, algorithmic bias, limited external validation, and regulatory uncertainty remain major barriers to implementation. Clinical translation requires multicenter RCTs, explainable AI frameworks, and standardized reporting guidelines such as Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis Artificial Intelligence (TRIPOD-AI).

8 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
Ajit BrarAjit Brar
Ajit Brar
AKAayushi Nilesh Kacheria
Aayushi Nilesh Kacheria
KPKaren Purewal
Karen Purewal
ASAustin Simister
Austin Simister
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes current and emerging therapeutic strategies aimed at addressing the shared pathophysiologic mechanisms driving CKM progression, such as insulin resistance, inflammation, oxidative stress, and neurohormonal activation. Established pharmacotherapies that include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and nonsteroidal mineralocorticoid receptor antagonists like finerenone have demonstrated robust efficacy in reducing cardiovascular events, slowing renal decline, and improving metabolic outcomes. Additionally, novel agents targeting lipoprotein(a), interleukin-6, and hepatic fat accumulation are expanding the therapeutic landscape. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to modulate lipoprotein(a) and PCSK9 expression. Artificial intelligence (AI) is also emerging as a transformative tool for personalized CKM management, enhancing risk prediction and clinical decision-making. The review highlights the relevance of metabolic dysfunction-associated steatotic liver disease (MASLD) as a CKM modifier and discusses the approval of resmetirom, a selective thyroid hormone receptor β agonist, for noncirrhotic MASH. By integrating evidence from clinical trials, mechanistic studies, and emerging technologies, this review provides a comprehensive resource for clinicians and researchers navigating the evolving field of CKM syndrome.

23 December 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MSMuhammad M. Saleem
Muhammad M. Saleem
MMMuhammad Mudassar
Muhammad Mudassar
Ajit BrarAjit Brar
Ajit Brar
AUAleena Usman
Aleena Usman
GGGurparvesh Goraya
Gurparvesh Goraya
VBVijyawant Brar
Vijyawant Brar
Pulmonary Vein Isolation (PVI) is considered to be the primary strategy for atrial fibrillation (AF) ablation. However, recurrence of AF and atrial tachyca

30 April 2026 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
MSMuhammad Saleem
Muhammad Saleem
MTMuhammad Haider Tariq
Muhammad Haider Tariq
MMMuhammad Mudassar
Muhammad Mudassar
Ajit BrarAjit Brar
Ajit Brar
AUAleena Usman
Aleena Usman
AZAnwar Zaitoun
Anwar Zaitoun
Background: Endovascular options for infrapopliteal artery disease include plain balloon angioplasty (PTA), drug‑coated balloons (DCB), drug‑eluting and bare‑metal stents (DES), and atherectomy. Retrievable scaffold therapy (RST) has recently emerged as a temporary scaffolding strategy used with DCB, but its comparative effectiveness remains uncertain. Methods: A comprehensive literature search identified 21 randomized and 4 single‑arm trials ( n = 3184). Eligible studies reported at least one prespecified outcome: 30‑day major adverse events (MAE), 12‑month all‑cause mortality, 6‑month clinically driven target lesion revascularization (CD‑TLR), or 6‑month major amputation. Random‑effects models generated odds ratios (ORs) with 95% credible intervals (CrIs). SUCRA values summarized treatment rankings. Results: Atherectomy ranked best for 30‑day MAE (SUCRA 77.2%), though no treatment yielded a statistically significant reduction in the Odds Ratio. It was also associated with a significantly reduced 12‑month mortality versus PTA (OR 0.39, 95% CrI 0.15–0.90; SUCRA 97.8%). For 6‑month CD‑TLR, atherectomy (OR 0.26, 95% CrI 0.00–0.62), DCB (OR 0.42, 95% CrI 0.30–0.58), and DES (OR 0.43, 95% CrI 0.19–0.88) showed significant benefit. No treatment significantly reduced major amputation. RST showed favorable but nonsignificant reductions, indicating a smaller number of available studies, consistently ranking mid‑tier across all outcomes. Meta‑regression identified CKD and longer lesion length as predictors of higher CD‑TLR risk. Conclusions: Atherectomy showed the most consistent benefits across mortality and reintervention outcomes, while RST demonstrated promising but inconclusive performance. Larger randomized trials are needed to clarify RST’s role in infrapopliteal revascularization.